<DOC>
	<DOCNO>NCT01889186</DOCNO>
	<brief_summary>This Phase 2 , open label , multicenter , study evaluate efficacy safety ABT-199 relapse refractory subject CLL harbor 17p13 ( TP53 locus ) deletion . One hundred seven ( 107 ) subject enrol main cohort , evaluation efficacy primary objective , approximately 50 subject enrol safety expansion cohort evaluate safety update tumor lysis syndrome prophylaxis management measure . Enrollment main cohort close . Enrollment safety expansion cohort close .</brief_summary>
	<brief_title>A Study Efficacy ABT-199 Subjects With Relapsed/Refractory Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Subject must great equal 18 year age . Subject must diagnosis CLL meet publish 2008 Modified IWCLL NCIWG ( International Workshop Chronic Lymphocytic Leukemia National Cancer InstituteWorking Group ) Guidelines . Subject indication treatment accord 2008 Modified IWCLL NCI WG Guidelines ; Subject clinically measurable disease ( lymphocytosis &gt; 5 × 10^9/L and/or palpable measurable node physical exam and/or organomegaly assess physical exam ) ; Subject must refractory relapsed receive least one prior line therapy ( subject progress 1 cycle treatment complete least 2 cycle treatment give line therapy ) previously untreated CLL ( previously untreated CLL subject must receive prior chemotherapy immunotherapy . Subjects history emergency , locoregional radiotherapy ( e.g. , relief compressive sign symptom ) eligible . In addition , subject must meet CLL diagnostic criterion must &gt; 5 × 109/L B Lymphocytes peripheral blood . ) ; Subjects must 17p deletion , assess local laboratory ( bone marrow peripheral blood ) assess central laboratory ( peripheral blood ) . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 . Subject must adequate bone marrow function Screening follow : Absolute Neutrophil Count ( ANC ) great equal 1000/µL , For subject ANC le 1000/µL Screening bone marrow heavily infiltrate underlying disease ( unless cytopenia clearly due marrow involvement CLL ) , growth factor support may administer Screening prior first dose ABT199 achieve ANC eligibility criterion ( great equal 1000/µL ) ; Platelets great 30,000/mm3 ( without transfusion support within 14 day Screening , without evidence mucosal bleeding , without know history bleed episode within 3 month Screening , without history bleed disorder ) ; Hemoglobin great equal 8.0 g/dL . Subject must adequate coagulation , renal , hepatic function , per laboratory reference range Screening follow : Activated partial thromboplastin time ( aPTT ) prothrombin time ( PT ) exceed 1.5 × upper limit normal ; Calculated creatinine clearance great 50 mL/min use 24hour Creatinine Clearance modify CockcroftGault equation ( use Ideal Body Mass [ IBM ] instead Mass ) . For subject BMI &gt; 30 kg/m2 &lt; 19 kg/m2 , 24hour measure urine creatinine clearance require ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less equal 3.0 × upper normal limit institution 's normal range ; Bilirubin le equal 1.5 × upper limit normal . Subjects Gilbert 's Syndrome may bilirubin great 1.5 × upper limit normal , per correspondence investigator AbbVie medical monitor . For subject high risk tumor lysis syndrome preapproval AbbVie medical monitor require prior enrollment . Subject undergone allogeneic stem cell transplant . Subject develop Richter 's transformation confirm biopsy . Subject prolymphocytic leukemia . Subject active uncontrolled autoimmune cytopenia ( 2 week prior Screening ) , include autoimmune hemolytic anemia idiopathic thrombocytopenic purpura despite low dose corticosteroid . Subject previously receive ABT199 . Subject receive biologic agent antineoplastic intent within 30 day prior first dose study drug . Subject receive follow within 14 day 5 halflives applicable prior first dose study drug , recover less Common Toxicity Criteria ( CTC ) grade 2 clinically significant adverse effect ( ) /toxicity ( ) previous therapy : Any anticancer therapy include chemotherapy , radiotherapy ; Investigational therapy , include target small molecule agent . Subject know allergy xanthine oxidase inhibitor rasburicase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>17 p Deletion</keyword>
</DOC>